Intravitreal Bevacizumab (IVB) for Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO).
To evaluate the effectiveness of intravitreal Bevacizumab in decreasing central macular thickness in branch retinal vein occlusion (BRVO) related macular edema. Quasi experimental study. Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi, Pakistan, from March to August 2017. Intravitreal Bevacizumab (1.25 mg/0.05 ml) was given in inferotemporal quadrant under aseptic conditions on monthly basis for consective three months. Post-injection, all the patients were followed up on monthly basis for consecutive three months. CMT (in µm) was measured by using OCT at baseline and after intravitreal Bevacizumab injections at one month, two months, and finally at three months. Forty eyes of forty patients were included in the study. There were 25 (62.5%) male patients and 15 (37.5%) female patients. Baseline mean CMT ±SD was 358 ±36 µm before IVB injection. Mean CMT was 252 ±12 µm at 3 months (after three IVB injections). At three months, mean percentage decrease in CMT was 29.60%. Intravitreal Bevacizumab is effective and results in decrease in central macular thickness to normal or near- normal levels in branch retinal vein occlusion (BRVO) related macular edema.